News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS)'s Gilenya Patient Develops Rare Brain Disease



4/13/2012 7:59:21 AM

A patient taking Novartis AG’s Gilenya multiple sclerosis pill has been diagnosed with a potentially deadly brain infection. The patient previously took Tysabri, an injection from Weston-based Biogen Idec Inc. and Elan Corp., Novartis said in an e-mailed statement. Tysabri increases the risk of the viral infection, known as progressive multifocal leukoencephalopathy, that usually leads to death or severe disability, according to a warning the drug’s label has carried since 2006.

Read at Boston Globe
Read at Pharmalot
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES